288 related articles for article (PubMed ID: 3897170)
21. Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity.
Jones RN; Thornsberry C
Rev Infect Dis; 1982; 4 Suppl():S300-15. PubMed ID: 6294779
[TBL] [Abstract][Full Text] [Related]
22. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
Spencer RC
Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
[TBL] [Abstract][Full Text] [Related]
23. In vitro antibacterial activity and beta-lactamase stability of CL 118523, an aminothiazolyl iminomethoxy cephalosporin.
Chin NX; Neu HC
Chemioterapia; 1987 Oct; 6(5):329-36. PubMed ID: 3322588
[TBL] [Abstract][Full Text] [Related]
24. The effects on beta-lactam susceptibility of phenotypic induction and genotypic derepression of beta-lactamase synthesis.
Shannon K; Phillips I
J Antimicrob Chemother; 1986 Dec; 18 Suppl E():15-22. PubMed ID: 3102451
[TBL] [Abstract][Full Text] [Related]
25. In vitro antibacterial activity of imipenem against Pseudomonas and Staphylococcus species. Comparison with thirteen other antimicrobial agents.
Cristiano P; Abbate GF; Alagia I; Leonessa V; Giaquinto E; Savioli L
Drugs Exp Clin Res; 1985; 11(1):39-48. PubMed ID: 3869802
[TBL] [Abstract][Full Text] [Related]
26. Comparative in vitro activity of CGP 31608, a new penem antibiotic.
Eliopoulos GM; Wennersten C; Reiszner E; Moellering RC
Antimicrob Agents Chemother; 1987 Aug; 31(8):1188-93. PubMed ID: 3498437
[TBL] [Abstract][Full Text] [Related]
27. In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Stamm JM; Hanson CW; Chu DT; Bailer R; Vojtko C; Fernandes PB
Antimicrob Agents Chemother; 1986 Feb; 29(2):193-200. PubMed ID: 3087274
[TBL] [Abstract][Full Text] [Related]
28. Isolates of β-lactamase-negative ampicillin-resistant Haemophilus influenzae causing invasive infections in Spain remain susceptible to cefotaxime and imipenem.
García-Cobos S; Arroyo M; Pérez-Vázquez M; Aracil B; Lara N; Oteo J; Cercenado E; Campos J
J Antimicrob Chemother; 2014 Jan; 69(1):111-6. PubMed ID: 23943391
[TBL] [Abstract][Full Text] [Related]
29. Comparative in vitro activity and beta-lactamase stability of CGP 31523A, a new aminothiazolyl cephalosporin.
Chin NX; Neu HC
Chemioterapia; 1986 Apr; 5(2):92-100. PubMed ID: 3518967
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of cefpirome (HR810) against antibiotic-resistant gram-positive and gram-negative bacteria including organisms with inducible resistance.
Murray PR; Niles AC
Diagn Microbiol Infect Dis; 1986 Jan; 4(1):53-63. PubMed ID: 3632921
[TBL] [Abstract][Full Text] [Related]
31. The in vitro antibacterial activity of ceftriaxone in comparison with nine other antibiotics.
Emmerson AM; Lamport PA; Reeves DS; Bywater MJ; Holt HA; Wise R; Andrews J; Hall MJ
Curr Med Res Opin; 1985; 9(7):480-93. PubMed ID: 3928265
[TBL] [Abstract][Full Text] [Related]
32. [The effect of cefepime on ceftazidime, cefotaxime and imipenem resistant strains of Acinetobacter, Xanthomonas, Pseudomonas, Flavobacterium, Sphingobacterium and on producers of extended spectrum beta-lactamases (ESBL) with resistance transfer].
Blahová J; Hupková-Lesická M; Králiková K; Krcméry V; Kubonová K
Cas Lek Cesk; 1997 Mar; 136(5):154-6. PubMed ID: 9221190
[TBL] [Abstract][Full Text] [Related]
33. Activity of imipenem on aerobic bacteria.
Acar JF; Goldstein FW; Kitzis MD; Gutmann L
J Antimicrob Chemother; 1983 Dec; 12 Suppl D():37-45. PubMed ID: 6421793
[TBL] [Abstract][Full Text] [Related]
34. N-formimidoyl thienamycin: in vitro comparison with cefoxitin and tobramycin against clinical, bacterial isolates.
Digranes A; Dibb WL; Benonisen E
Acta Pathol Microbiol Immunol Scand B; 1983 Apr; 91(2):141-4. PubMed ID: 6603093
[TBL] [Abstract][Full Text] [Related]
35. [In vitro antimicrobial activity of cefpirome compared to other broad-spectrum beta-lactam drugs against 804 clinical isolates from 9 Brazilian hospitals].
Sader HS; Mendes CM; Montelli A; Sampaio J; Segura AJ; Kesselring GL; Costa L; Ribeiro JE; Mamizuka E; Mimiça I
Rev Assoc Med Bras (1992); 1998; 44(4):283-8. PubMed ID: 9852647
[TBL] [Abstract][Full Text] [Related]
36. [In vitro antibacterial activity of a new cephalosporin: cefpirome (HR 810). Comparison with ceftriaxone, cefotaxime, latamoxef and ceftazidime].
Le Noc P; Bryskier A; Le Noc D
Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):567-71. PubMed ID: 3534744
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
38. In-vitro activity of Sch 34343 against Gram-negative bacteria producing characterized beta-lactamases.
Dornbusch K; Frolander F; Cacciapuoti AF; Naples L; Hare RS; Miller GH
J Antimicrob Chemother; 1985 Jun; 15 Suppl C():85-97. PubMed ID: 3897175
[TBL] [Abstract][Full Text] [Related]
39. In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin.
Vuye A; Pijck J
Antimicrob Agents Chemother; 1985 Apr; 27(4):574-7. PubMed ID: 3859244
[TBL] [Abstract][Full Text] [Related]
40. In-vitro activity of Sch 34343, a new penam, against gram-positive isolates from cancer patients.
Rolston KV; Alvarez ME; Hoy JF; Alderman HC; Ho DH; Bodey GP
J Antimicrob Chemother; 1986 Aug; 18(2):159-62. PubMed ID: 3093447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
